idrx-42
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2022 (NCT05489237)
Timeline
Indications
Mechanism of action
- Stem cell growth factor receptorINHIBITOR
KIT inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1cc(-c2ccc(CNc3cc(-c4cnc5cc(OCCCN6CCCC6)ccn45)ncn3)cc2)cn1- Mol. weight
- 508.63 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314917 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07218926 | Phase 3 | Oct 30, 2025 | GlaxoSmithKline |
| NCT05489237 | Phase 1 | Aug 1, 2022 | IDRx, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2025 |
| IDRx, Inc. | For profit | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1